From: Jennifer Ott <[email protected]>
Sent: Tuesday, July 18, 2023 12:28 PM
To: Kylie Alsofrom <[email protected]>
Ce: Krista Kim <[email protected]>; Pooja Gill <[email protected]>; Andrew Thomas < [email protected]>; CMAdmin <[email protected]> Subject: RE: [EXTERNAL] Science Corporation and Building 11 Hello Kylie:
29/485
I'd be happy to meet with you. I leave tomorrow on vacation, but could meet when I get back during the week of 8/7. I'd also bring Andrew Thomas, the Interim Base Reuse and Economic Development Director. I've cced our admin team so they can work with you to find a time to Looking forward to meeting and building a strong partnership with you as well! Thanks,
Jen
From: Kylie Alsofrom <[email protected]>
Sent: Tuesday, July 18, 2023 10:44 AM
To: Jennifer Ott <[email protected]?
Ce: Krista Kim < [email protected]>; Pooja Gill <[email protected]? Subject: [EXTERNAL] Science Corporation and Building 11 Hi Ms. Ott,
I hope you have been well. I am reaching out in hopes of setting up a conversation with you and our CEO, Max Hodak. We are very excited about the prospect of Building 11! We have sent our redlined version of the lease, but thought it would be a good idea to connect with you to discuss our high level plans to ensure we are in alignment with the future of Building 11. Along with ensuring lease negotiations progress smoothly, it is ultimately our goal to work with you to build a strong partnership with the city of Alameda.
Looking forward to connecting,
--
Kylie Alsofrom
Director of Operations
P: 510.871.2567 ext 105 W: Science.xyz
From: Jennifer Ott on behalf of Jennifer Ott <[email protected] To: Andrew Thomas
Subject: RE: [EXTERNAL] Science Corporation update
Date: Monday, August 7, 2023 4:37:06 PM
Attachments: image001.png
Is this getting resolved? Should we talk about when we meet with the leasing team? From: Andrew Thomas <[email protected]>
Sent: Tuesday, July 18, 2023 9:16 PM
To: Jennifer Ott <[email protected]>
Subject: Fwd: [EXTERNAL] Science Corporation update
Andrew Thomas,
REDACTED
Begin forwarded message:
From: John McManus/USA <[email protected]>
Date: July 18, 2023 at 7:16:36 PM PDT
To: Andrew Thomas <[email protected]>, Scott Watson <[email protected]>, Simon Adams <[email protected]>, Brenda Lin <[email protected]>
Cc: Ted Anderson/USA <[email protected]>, Andrew Schmieder/USA <[email protected]>
Subject: [EXTERNAL] Science Corporation update
Hello Team - when I read the Science Corp redline draft of the Lease, I identified three significant business point issues. In the interest of being as efficient as possible with our time, I reached out to their representatives for clarification. These are the issues:
1. Language around Prevailing Wage in section 26.4 and elsewhere. They have given me assurances that this issue was a misunderstanding on their part and they will comply, so l am comfortable we can resolve to everyone's satisfaction.
2. Section 10.5 as it relates to the escrow of funds intended for Capital Repair credits. They pushed back on this concept, which is a concern. In conversation, I feel comfortable now that this is an issue that we can reach agreement on in some form.
3. In Section 6.1 they added language asserting their right to keep animals on the Premises, which raised a number of questions for me. It turns out that they plan to build a vivarium, initially for mice and rabbits and later for a "colony of non-human primates," their words This is part of their research, which includes an operating room for inserting their implants into animals. Science assures me that they comply with all FDA regulations and other conventions in this work, 503/649
and I don't have any reason to doubt them. But I am also aware that a vivarium is something that may cause concern for the Council and the public, so I think it is something that needs to be socialized before we go too deep in this process, certainly well before any public hearing. The Science representative that I spoke with says that when the Mayor visited their current location, they explained the operation in full, including showing her the operating room. My understanding is that the Mayor continues to be a supporter of this tenant, so if they were indeed candid about the use, that is a positive. Nonetheless, I think we need to double check this so that the public discourse doesn't get ahead of us on what could be a sensitive topic
Happy to discuss this in more detail if that will be helpful. Thanks.
John H. McManus, MCR, CCIM
Vice Chairman
Brokerage Services
CA License 01129064
Direct: +1 510 891 5817
Mobile: +1 510 414 2949
[email protected]
CUSHMAN &
WAKEFIELD
555 12th Street, Suite 1400
Oakland, CA 94607 | USA
cushmanwakefield.com
Linkedln | Eacebook | Iwitter | YouTube I Instagram
From: Kylie Alsofrom <[email protected]> on behalf of Kylie Alsofrom <[email protected]> To: Andrew Thomas
Sent: 8/25/2023 2:45:52 PM
Subject: Re: ScienceCorp Staff Report 7 August 2023
Hi Andrew,
Thank you so much for sending this along. We had a chance to review and overall everything looks good.
The only thought I have is that you may not need the sentence "We understand these to include mice, rabbits and non-ape primates and are typical for research uses such as this." I would recommend sharing this information if asked, but perhaps don't need it in report. This is completely up to you and your disgrection, that is the only thing that stood out to me.
Have a great weekend,
Kylie
On Thu, Aug 24, 2023 at 4:35 PM Andrew Thomas < [email protected]> wrote:
Kylie: This is not complete or public. I would appreciate your review and comment. Please feel free to suggest additional or changes in Track Changes.
Andrew
Kylie Alsofrom
Director of Operations
P: 510.871.2567 ext 105 W: Science.xyz
64/485
дуни
On Wed, Oct 11, 2023 at 5:46 PM Kylie Alsofrom <[email protected]> wrote:
Hi Abby,
285/485
Thanks for chatting. Here are some times we are available for tours:
• Monday: 1pm or 3pm
• Tuesday 4pm or 5pm
Kylie
On Tue, Oct 10, 2023 at 10:28 PM Kylie Alsofrom <[email protected]> wrote:
Hi Abby,
I am happy to coordinate a tour. Let me know how you would like me to coordinate.
Can you share more about the ask for photos of the vivarium so I can understand th urpose of the images. We don't currently have pictures of the spac Kylie
On Tue, Oct 10, 2023 at 12:02 PM Abby Thorne-Lyman <[email protected]> i Pooja and Kylie, please see request below and let us know who would be point ontact for CM Spencer (as well as the vivarium reques
Abby Thorne-Lyman (she/her)
Director
Base Reuse and Economic Development
City of Alameda
[email protected]
REDACTED
From: Jennifer Ott <[email protected]>
Sent: Tuesday, October 10, 2023 11:23 AM
o: Abby Thorne-Lyman <[email protected]
'c: Andrew Thomas <[email protected]
Subject: Science Corp Agenda Item - CM Spencer
Hello Abby:
286/485
CM Spencer would like to tour existing Science Corp facility? Can you check to see if hey are willing to tour her and if so, who should she contact? Also, she would lik pictures of the vivarium added to agenda? Would they be willing to provide those Thanks,
Jen
On Oct 16, 2023 8:25 PM, Max Hodak <[email protected]? wrote:
Dear Alameda
City Council,
Science, we are developing advanced medical devices for serious unmet medical needs. Our first program is the Science Eye retinal prosthesis for patients who sufler from profound blindness due to rod-cone dystrophies such as retinitis pignentosa and dry macular degeneration. These patients watch their vision dwindle over years until only spots of light are left, which today is completely irreversible.
There
have been prior commercial attempts at visual prostheses, but none with the potential to achieve single-neuron resolution, which is necessary to restore high-resolution vision to the brain. We hope to offer patients who have spent many years in darkness the abilitv to see their childrens' faces again, or the independence to walk across town on their own to buv coffee therapies, alongside every other medical device and drug trom pacemakers to paxlovid, require anımal research as mandated by the FDA and regulated by the USDA. While recent legislation allows the FDA to consider evidence other than animal studies, FDA reviewers
and consultants have significant discretion in what they ask for, and they have told us through formal feedback that they require animal studies in order to seck approval for a first-in-human clinical trial in the US. ine
FDA Modernization Act cites a range of new tools, including induced pluripotent stem cells, artificial intelligence, and organoid teo omes as atemaves to amm stuaes, we use aonmese ouatontmktemev arre ony amanda sosteure als 471/485
is fundamentally a scientific technical limitation: in an ideal world no animal testing would be required, but today there is no other source of the critical safetv and efficacy data used to justifv risking a human patient, requirements imposed by federal regulators. Personally, I believe there are often opportunities that make sense to go into human patients earlier than we do today, and would love to discuss FDA reform with anyone who will hear me, but on our path to reaching patients today this is not our call to nake
i ne
species we use and the number of each is based on a dialog with those regulators. For example, whether we can use only rabbits or if some primate studies will be required is an active topic of discussion between our regulatory team and the FDA. If primato studies are required, it is possible we could do them elsewhere than Alameda Point.
With
the complexity of our studies, it is not feasible to outsource them. Our vertical integration, where our electrical engineers are only a few steps from our surgeons and our stem cell biologists, is a key element of why we have been able to move as fast as we have in our two years of existence. Dividing the company would result in higher costs and longer timelines to reach patients polenually even lowering the chance it reacnes them at all.
Ine
medicines we develop involve gene and cell therapies, and if they reach patients will be among the most complex pieces of biotechnology to ever reach the clinic. The assertions by PCRM that there are alternatives which don't require testing, such as focused ultrasound or non-invasive electrical stimulation are not rooted in reality. If there were a non-invasive, wearable device that could be built to restore vision to patients, believe me, we would be building that instead. I have a family history of retinitis pigmentosa and grew up around it. It is hurtful for these groups to simply hand-wave away potential progress citing other technologies they do not understand which do not in fact work in the way they are suggesting. for ine Neuralink alleeatons. I really cannot speak tor them as am sul under NDA trom mv time tnere, but will sav ue recen pressure campaign coverage is a heavy mischaracterization of the facts. I know the Neuralink animal care team cares deeply aboul ammar wellare and follows standards tar in excess or tradiuonal qudelnes. Not many companies try to reure ammais lo sanctuary, but Neuralink has invested in doing just that when appropriate. In response to PCRM's campaign, they have written a handful
ot articles providing more context on PCKM's claims. You can tind those articles here:
https://neuralink.com/blog/neuralink-s-commitment-to-animal-welfare/ https://neuralink.comblog/championing-tne-3-Ts/
nus. neura nk. com olow nusoandry-rennenen
https://neuralink.com/blog/environmental-enrichment/
https://neuralink.com/blog/the-role-of-the-institutional-animal-care-and-use-committee/ furtner.
per public information, all of the records cited by PCRM are from the California National Primate Research Center at UC Davis under protocols approved bv their Institutional Animal Care and Use Committee. All of that work was reviewed and monitored bv al panel
of UC Davis faculty per
field standards. Further, the 2021 pig study they reference happened after I had left the company, and I had no part in its design or implementation; all I know about it is from news articles. science we are developing very dinerent technology than Neuralink, and accordingly the species we nave to use are different Regardless, we commit to following the same high standards as evidenced in those blog posts, and doing what we can to give our 472/485
research
animals exceptional housing conditions and empower our vet med staff to provide the best possible care. All of this is regulated by the US Department of Agriculture, whose reports are public records, and who make unannounced inspections at least once a vear in addition to responding to complaints.
The
Science Eye is the first in a range of devices we plan to announce over the coming years, each focused on a different critical unmet medical need. More is possible than many believe today, and 1 am confident that the coming years are going to be surprising.
We feel a deep moral obligation to bring these innovations to patients who can benefit from them the most.
DUC
to the nature of our operations, it is difficult to keep moving the company every few years as we outgrow facilities. Animal research is only a small part of what we do: the rest of the company needs highly-rated cleanrooms and extensi ve technical infrastructure.
Moving all of this is extremely disruptive and complex. Our goal is to put down roots and spend the next several decades investing in our community and growing to be valuable members of the Alameda Point community. I have spent several years searching the Bay Area for this home, and we have no runner up. I am convinced that Alameda Point will be a highlight of the whole Bay Area by the end of this decade. We would love to be part of that as we work towards bringing these important therapies to patients. you nave any questions, I can be flexible at your convenience to discuss further. hank
Max
From: "Max Hodak" <[email protected]>
Sent: 10/16/2023 10:09:01 PM (-07:00)
To: "Jennifer Ott" <[email protected]>; "Abby Thorne-Lyman" <[email protected]> Subject: [EXTERNAL] Fwd: A letter from Science Corp
I would like to be as helpful as possible but I am also anxious about how some of this would be used tomorrow.
If the City was serious about having biotech and felt that fully answering Councilmember Herrera Spencer's questions below was a condition of that, you could require transparency at the IACUC protocol level, which contains all of this information. I worry that would simply cause more activists to spend more time with us, but there are many levers the city could pull to effect a granular level of transparency if the people so demanded.
I'm trying to carefully think through my reply before I send something, but if you have any advice for me I would appreciate it!
Sent from my iPhone
On Oct 16, 2023, at 10:25 PM, Max Hodak <[email protected]> wrote:
I'm sorry for the misunderstanding. We currently use rodent caging from Innovive and rabbit caging from Allentown. Over time, I want to shift to building animal housing ourselves, so we can build larger modular spaces that give much more volume for a full range of naturalistic behaviors compared to what you see in traditional facilities. We collaborate with zoo designers to develop these enclosures, and our goal is to create large social play spaces that can be instrumented such that our scientific tasks can be largely phrased as naturalistic behavior.
You can find USDA facility inspection records here: https://aphis.my.site.com/PublicSearchTool/s/inspection- reports
The form doesn't change the URL so I can't easily share the results, but if you put "Science Corporation" (or "Neuralink") into the "Customer/Organization Name" field, click Search, and then click the "View Inspection Reports" tab, you can see the list of prior inspection with summary results and a downloadable report. You can see that neither Neuralink nor Science have any records of citations of any kind, including Teachable Moments.
As for my comments about Jurassic Park, while I'm a strong supporter of conservation efforts, that was not meant to be a serious proposal.
On Mon, Oct 16, 2023 at 9:50 PM Trish Spencer <[email protected]> wrote:
Dear Mr. Hodak,
Thank you for this email.
I also want to take this opportunity to thank you for the tour of part of your facility at 1010 Atlantic this afternoon. I requested the tour because I'm interested in how the animals are cared for, housed, procedures and anticipated procedures that they are/will be used for, etc. I apologize if that was not communicated to you by staff prior to our tour.
None/minimal of that information was available today. As we were not allowed to see any animals, how/where they're housed, I reiterated my request for pictures, illustrations, etc.
I reviewed the videos you attached from Neuralink, the company you were previously involved with. While I appreciate seeing the animals interacting with employees playfully, I didn't see videos of how the animals are housed, of any surgeries, etc.
As you're seeking to lease public property, I believe that the public and Councilmembers have a right to know 470/485
what will happen on their/public property if leased to your company.
I would also be interested in reviewing any public documents that you may be able to share that could bring transparency to what your company does currently and plans to do with the animals (e.g., what are the conditions of where they will reside, what type of animals, what scientific procedures will be performed on them, what happens to them after the procedures, etc.). You reference U.S. Department of Agriculture reports. Do you have any of those for review?
It is my understanding that your company seeks a 10 year lease, with two 5 year extensions for a maximum of 20 years. What is the maximum number of animals and types thereof that would be housed on the City property during that time? What would their cages/housing look like? What types of procedures will be conducted on them? What happens to the animals after the experiments? Also, there are statements online attributed to you regarding Jurassic Park, species diversity, etc. Would you like to respond to those?
https://www.cnet.com/science/no-elon-musks-neuralink-doesnt-have-tech-to-build-jurassic-park/ Thank you for any information that you can provide to assist with this important decision.
Sincercly,
Trish Herrera Spencer
Councilmember
510-552-0555
< Abby Texts (2)
Lisa Cooper
From: Abby Thorne-Lyman
Sent: Monday, November 20, 2023 12:33 PM
To: Lisa Cooper; Alexis Krieg
Subject: Re: PRA 23-526
My texts are attached
‹ Abby Texts (2) L Q:
12:31
< KA
No problem
In my experience they'll go thru
in room first then onto zoom
comments next. Folks just need
to know to raise hand when item
7B comes up
Ok sounds good.
How will Max get the slides set
up
Tue, Oct 17 at 11:30 PM
Ugh. I'm so sorry. That was so
very painful in all ways. I really
appreciate what Max said to
close it out. It needed to be said
that this was a choice about life
sciences. I'm wishing you all the
best and happy to regroup if
needed. You're still an important
Alameda business!!
Thank you so much for all of your
help with everything.
Text Message
Sent from my iPhone
On Nov 20, 2023, at 12:27 PM, Lisa Cooper <[email protected] Hello,
We received a PRA for: all emails, texts, letter, documents from January 1, 20. from Max Hodak and/or Science Corp (including his/their representatives, cor City staff (including City's agents to lease or sell City property) and/or City Col I have already produced emails. Please forward me any texts from Max Hodak Thank you, Lisa
Lisa K. Cooper
Administrative Services Coordinator
City of Alameda
spea
80W6-CZ0Z
suns x5
EZ0Z/LL/OL
127010027 100003A MOS No Seau Scoolen Mine A Hono Canna MASA AMoncina 1x01
he e be e emee a bana
sa задамо *ашки]
sa ezee ge ee a due swalloba